AL-S Pharma Presents Phase 2 AP-101 Data at ENCALS 2026, Highlighting Potential Disease-Modifying Effects in ALS AL-S Pharma AG, a clinical-stage biotechnology company focused on developing antibody therapies against misfolded proteins associated with amyotrophic lateral sclerosis (ALS), has presented new…
VectorBuilder and MaxCyte Partner to Develop Next-Generation Non-Viral Gene Delivery Platform for Ex Vivo Cell Therapies VectorBuilder and MaxCyte have entered into a strategic partnership aimed at developing a next-generation non-viral gene delivery platform for ex vivo cell engineering, a…
AdvanCell Establishes U.S. Global Headquarters in Greater Boston, Expands Manufacturing Footprint to Support Radiopharmaceutical Growth AdvanCell, a clinical-stage radiopharmaceutical company focused on developing targeted alpha therapies for cancer, has announced a major step in its global expansion strategy with the…
Syntax Bio Expands Series A to $14.4 Million, Strengthens Leadership Team and Advances Cell Programming Platform for Type 1 Diabetes Therapies Syntax Bio, a synthetic biology company focused on programming the next generation of cell therapies, has announced a significant…
Align Technology Names Kevin Conroy Board Chairman as Longtime Chair Ray Larkin Begins Leadership Transition Align Technology, Inc., the global medical device company best known for its Invisalign clear aligner system and broader portfolio of digital dentistry technologies, has announced…
Imperative Care Reports New SYMPHONY-PE Analysis Highlighting Potential Benefits of Early Thrombectomy as Symphony Use Surpasses 500 U.S. Patients Imperative Care, a medical technology company focused on improving treatment options for patients with thromboembolic disease, has announced new clinical findings…
Gossamer Bio Announces Final Results of Convertible Notes Exchange Offer, Strengthening Financial Position Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on advancing therapies for pulmonary hypertension, has announced the final results of its previously disclosed exchange offer involving its…
Hologic Secures Major Patent Victory Against Siemens in European Mammography Technology Dispute Hologic has announced a significant legal victory in Europe after the Unified Patent Court (UPC) in Germany ruled that Siemens Healthineers infringed a key Hologic patent related to…
Emmecell Secures Strategic Financing to Advance Magnetic Cell Delivery Technology for Ophthalmic Diseases Emmecell, a clinical-stage biotechnology company focused on developing innovative magnetic cell delivery technologies for the treatment of ophthalmic disorders, has announced the successful completion of a strategic…
Sumitomo Pharma America Highlights New Clinical and Translational Research for Nuvisertib and Enzomenib at EHA 2026 Sumitomo Pharma America, Inc. (SMPA) has unveiled new clinical and translational research findings at the 2026 Congress of the European Hematology Association (EHA), showcasing…
Atara Biotherapeutics Announces Board Transition, Welcomes Veteran Investor Brian Cherry as Director Atara Biotherapeutics, Inc., a clinical-stage biotechnology company focused on advancing T-cell immunotherapies for cancer and autoimmune diseases, has announced a significant change to its Board of Directors. The…
Xeris Receives USPTO Notice of Allowance for New Patent Covering KEVEYIS®, Extending Potential Protection Through 2039 Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc., has announced a significant intellectual property milestone for KEVEYIS® (dichlorphenamide), its FDA-approved treatment…